新发IV期乳腺癌原发灶早期局部治疗:随机临床试验(EA2108)结果
新发IV期乳腺癌且原发灶完整者接受4-8个月全身治疗后无进展者随机分组,早期局部治疗组与继续全身治疗组3年OS分别为68.4%与67.9%(HR=1.11,90%CI 0.82-1.52,P=.57),局部进展3年率16.3% vs 39.8%(P<.001),生活质量两组大致相似。
要点
- 早期局部治疗未改善新发IV期乳腺癌原发灶完整患者的生存(HR=1.11,90%CI 0.82-1.52)。
- 局部治疗组3年局部进展率16.3%,低于继续全身治疗组的39.8%(P<.001)。
- 两组生活质量评估结果大致相似。
核心结论
- 原发灶早期局部治疗未改善新发转移性乳腺癌患者的生存,虽改善局部控制但对生活质量无总体影响。
研究设计与样本
- 随机临床试验EA2108,入组390例,256例随机分配:131例继续全身治疗,125例接受早期局部治疗(按非转移性疾病标准行手术和放疗)。
- 入组患者先接受4-8个月全身治疗,无疾病进展者才随机分组。
- 主要终点为OS;局部控制和生存质量为次要终点;试验设计对随机化患者3年OS率19.3%绝对差异的检测效能为85%。
主要发现
- 3年OS:继续全身治疗组67.9% vs 早期局部治疗组68.4%(HR=1.11;90%CI 0.82-1.52;P=.57)。
- 中位OS:全身治疗组53.1个月(95%CI 47.9至未达),局部治疗组54.9个月(95%CI 46.7至未达)。
- 3年局部进展率:局部治疗组16.3% vs 继续全身治疗组39.8%(P<.001)。
- 生活质量指标两组间大致相似。
关键数值与推荐
- 主要终点OS:3年OS率全身治疗组67.9% vs 局部治疗组68.4%,HR=1.11(90%CI 0.82-1.52,P=.57)。
- 次要终点局部进展:3年局部进展率局部治疗组16.3% vs 全身治疗组39.8%(P<.001)。
- 中位OS:全身治疗组53.1个月(95%CI 47.9至未达)vs 局部治疗组54.9个月(95%CI 46.7至未达)。
临床怎么用
- 原文结论为原发灶早期局部治疗未改善新发转移性乳腺癌患者的生存;原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Distant metastases are present in 6% or more of patients with newly diagnosed breast cancer. In this context, locoregional therapy for the intact primary tumor has been hypothesized to improve overall survival (OS), but clinical trials have reported conflicting results. METHODS: Women presenting with metastatic breast cancer and an intact primary tumor received systemic therapy for 4-8 months; if no disease progression occurred, they were randomly assigned to locoregional therapy for the primary site (surgery and radiotherapy per standards for nonmetastatic disease) or continuing sysmetic therapy. The primary end point was OS; locoregional control and quality of life were secondary end points. The trial design provided 85% power to detect a 19.3% absolute difference in the 3-year OS rate in randomly assigned patients. The stratified log-rank test and Cox proportional hazards model were used to compare OS between arms. Cumulative incidence of locoregional progression was compared using Gray's test. Quality-of-life assessment used standard instruments. RESULTS: Of 390 participants enrolled, 256 were randomly assigned: 131 to continued systemic therapy and 125 to early locoregional therapy. The 3-year OS was 67.9% without and 68.4% with early locoregional therapy (hazard ratio = 1.11; 90% CI, 0.82 to 1.52; P = .57). The median OS was 53.1 months (95% CI, 47.9 to not estimable) in the systemic therapy arm and 54.9 months (95% CI, 46.7 to not estimable) in the locoregional therapy arm. Locoregional progression was less frequent in those randomly assigned to locoregional therapy (3-year rate: 16.3% v 39.8%; P < .001). Quality-of-life measures were largely similar between arms. CONCLUSION: Early locoregional therapy for the primary site did not improve survival in patients presenting with metastatic breast cancer. Although it was associated with improved locoregional control, this had no overall impact on quality of life.
引用
- Khan SA, Zhao F, Goldstein LJ, et al. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108). J Clin Oncol. 2022. PMID: 34995128. doi:10.1200/JCO.21.02006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。